Get started
Cue Biopharma, Inc.Cue Biopharma, Inc.Cue Biopharma, Inc.

Cue Biopharma, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

CUE trade ideas

CUE Symmetrical Triangle Breakout Setup - Entry, Targets & SL! Entry Point: Around $1.60, marked with the yellow line. Stop Loss (SL): At $1.50, marked with the white horizontal line. Target 1 (T1): At $1.73, represented by the red horizontal line. Target 2 (T2): At $1.93, represented by the green horizontal line. #CUE #StockTrading #BreakoutStrategy #SymmetricalTriangle #TechnicalAnalysis #TradingSetup #StockMarket #SwingTrading #DayTrading #ChartPatterns #RiskManagement #TradingSignals #PriceAction #ProfitToPath #StockTraders #TradingGoals #TradeSmart #StockBreakout #StockAnalysis
NASDAQ:CUELong
by ProfittoPath
CUE - Downdtrend Breakout & Upcoming CatalystsCue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others. Disclaimer: This content is for informational purposes only and is not intended as financial advice. Upcoming Catalyst: Date: 23/05/2024 Details: Expecting a pre-run-up into the data release. Investment Overview (Dated 03/05/2024): Relative Volume: 2.35 Shares Float: 47.07 million Short Float: 10.15% Financial Health: Cue Health Inc. (HLTH) has a debt-to-equity ratio of 0.19, showing relatively low debt compared to equity. A current ratio of 2.54 and a quick ratio of 1.91 indicate sufficient liquidity for short-term obligations. Key Technical Levels: Resistance Levels: Watch for resistance at $2.50, $2.75, $3.60, and $4.40. Breaking above these thresholds could indicate upward movement, where taking partial profits may secure gains. Trading Strategy: Take Profit (TP): Aim for a profit target at around $6.80 for maximum returns. Stop Loss (SL): Place a stop loss below $1.50 to limit potential losses. Chart Analysis: Refer to the accompanying chart for a detailed visual analysis of price movements and trend lines. Trading Caution: Trade with careful consideration of market conditions and personal risk tolerance. Conduct thorough research or consult a financial advisor before making investment decisions.
NASDAQ:CUELong
by meitshels_smell_trades
4
Cue Biopharma, IncOn the above two Weekly chart price action has corrected almost 90% since June 2020. A number of reasons now exist to be bullish , including: 1) A strong buy signal prints (not shown). 2) Regular bullish divergence . Multiple oscillators printing divergence. 3) Price action confirms support on past resistance. 4) Falling wedge breakout + backtest. Is it possible price action falls further? Sure. Is it probable? No. Ww Type: trade Risk: <=6% of portfolio Timeframe: Don’t know. Return: Don’t know Stop loss: <=$2.15
NASDAQ:CUELong
by without_worries
6
Tutorial: Super simple buying and selling stocks in Trading ViewJust thought I would create a quick video to show how easy it is to buy and sell stocks within Trading View. I use Trade Station as the broker - Note: You need to use the US Trade Station. I dont think the International Trade Station works with Trading View. If you would like to sign up to Trading View would be great if you could use my link so we both get $30 towards our trading. www.tradingview.com
NASDAQ:CUEEducation
by zAngus
39
$CUE:NASDA - CUE BIOPHARMA - 100% run over the last month.Cue has been having a great run of late - up 100% over the last month and up a bit over 200% over the last 6 months. Its been running pretty hard for a while so might be overextended, but I like what they do and could be worth a watch. Be careful of pullbacks. Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.
NASDAQ:CUELong
by zAngus
1
Cue Biopharma, Inc. On breakout alert $cueOn breakout alert today. Looking for entry on backtest and confirmation of support Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.
NASDAQ:CUE
by Bullishcharts